TRIUMPH-2 vs TRIUMPH-3: Diabetes vs Obesity Arms

Retatrutide has already shown what it can do in Phase 2. The Phase 3 TRIUMPH program is where it either earns FDA approval or doesn't — and understanding why the program uses separate trial arms for type 2 diabetes and obesity tells you a lot about how metabolic drug development actually works.

TRIUMPH-2 targets type 2 diabetes. TRIUMPH-3 targets obesity. Same drug, same mechanism, different populations, different endpoints, different clinical questions. Both need to read out positively for retatrutide to reach its full potential as a treatment option.

What Retatrutide Is

Retatrutide (LY3437943) is Eli Lilly's triple agonist — it activates three receptors simultaneously: GLP-1, GIP, and the glucagon receptor. For context, semaglutide is a GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor activation on top.

The glucagon piece is what makes the mechanism distinct. Glucagon is classically known as a counterregulatory hormone that raises blood sugar — which is why adding glucagon activation seems counterintuitive in a drug targeting diabetes and obesity. But what the glucagon receptor activation actually does in this context is increase energy expenditure. When glucagon signaling is activated in the liver and brown adipose tissue, the body burns more energy at rest. It adds a thermogenic component that GLP-1 and GIP don't provide on their own.

The Phase 2 results were striking. In the 2023 NEJM publication (Jastreboff et al.), adults without diabetes receiving 24 mg of retatrutide weekly for 48 weeks lost a mean of approximately 24.2% of body weight at that dose. That's higher than what was seen with semaglutide in STEP-1 (14.9% at 68 weeks) or tirzepatide at 15 mg in SURMOUNT-1 (20.9% at 72 weeks), though direct comparison across trials with different populations and time points has significant limitations.

Phase 2 data isn't approval data. TRIUMPH is where the definitive test happens.

Why Separate Trials for Diabetes and Obesity?

The split isn't bureaucratic — it's scientific and regulatory.

In drug development, a primary endpoint is the single most important measure the trial is powered to detect. The FDA grants approval based on whether a drug meets its primary endpoint with statistical significance. Choose the wrong primary endpoint, or design a trial around a population where that endpoint is diluted, and you can fail even if the drug genuinely works.

For obesity without diabetes, the primary endpoint is percentage body weight loss at the trial endpoint. The FDA expects a weight-loss drug to either: (a) produce at least 5% mean weight loss greater than placebo, or (b) achieve a specific responder threshold (e.g., ≥5% weight loss in at least 35% of patients, roughly twice the placebo rate). Body weight is the main event.

For type 2 diabetes, the regulatory story is more complex. Glycemic control — specifically HbA1c reduction — is the traditional primary endpoint for diabetes drugs. Weight loss is a secondary benefit. A diabetes trial also needs to demonstrate cardiovascular safety, either through an embedded safety analysis or a dedicated cardiovascular outcomes trial.

Running both populations in the same trial would either: (a) dilute the diabetes population's glycemic outcomes with people who don't have diabetes, (b) dilute the obesity population's weight-loss outcomes with people whose weight loss is complicated by diabetes medications, or (c) require an impossibly large sample to be powered for both endpoints simultaneously. Separate trials are the practical solution.

TRIUMPH-2: The Diabetes Arm

TRIUMPH-2 enrolls adults with type 2 diabetes who are inadequately controlled on background therapy. The primary objective is HbA1c reduction — demonstrating that retatrutide improves glycemic control compared to placebo (or an active comparator) over the trial period.

Secondary endpoints include weight loss, which is expected to be clinically meaningful based on the Phase 2 data. In the Phase 2 diabetic subgroup, retatrutide produced substantial HbA1c reductions alongside significant weight loss — the dual benefit that made tirzepatide (Mounjaro) a commercial success before its weight-loss approval followed.

The diabetes arm also needs to characterize hypoglycemia risk. Retatrutide's GLP-1 component drives insulin secretion in a glucose-dependent manner, which generally limits severe hypoglycemia risk — but the glucagon component adds complexity. Glucagon typically raises blood glucose, which might provide a natural counterbalance. How these effects interact in the context of background diabetes medications is something the trial will characterize with precision.

A diabetes cardiovascular outcomes trial may be required separately, or cardiovascular safety may be established through the SELECT-style inclusion of high-risk patients in TRIUMPH-2's design. The exact structure has not been publicly detailed as of this writing.

TRIUMPH-3: The Obesity Arm

TRIUMPH-3 enrolls adults with obesity without type 2 diabetes — typically defined as BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity. The primary endpoint is percentage body weight loss at the trial's end point, likely at 48 or 72 weeks.

This is the trial that will determine whether the Phase 2 numbers hold in a larger, more heterogeneous Phase 3 population. Phase 2 trials are optimized; Phase 3 populations include the full range of adherence, background medical complexity, and dose tolerability that real-world prescribing looks like.

The key questions TRIUMPH-3 will answer:

• Does the 24% mean weight loss replicate? Phase 2 was small enough that results can be inflated. Phase 3 typically brings numbers somewhat down from Phase 2 optimism.
• What does the safety profile look like at scale? Rare adverse events don't appear in Phase 2. Cardiac rate effects (glucagon receptor activation can increase heart rate), liver enzyme changes, and gastrointestinal tolerability will all be characterized more precisely.
• What is the responder distribution? Phase 2 showed high average weight loss, but what fraction of TRIUMPH-3 patients hit clinically meaningful thresholds (≥10%, ≥15%, ≥20% loss)?
• How does it compare to tirzepatide? Lilly develops both drugs. A head-to-head comparison may or may not be built into the TRIUMPH-3 design — that's a strategic decision that hasn't been publicly confirmed.

The Glucagon Question

The most clinically interesting design challenge in the TRIUMPH program is the glucagon component's effects in diabetes.

In a non-diabetic person, glucagon's blood-sugar-raising effect is counteracted by the GLP-1-driven insulin secretion. In a person with type 2 diabetes, the insulin secretion response is impaired. This raises a theoretical concern: could the glucagon activation worsen glycemic control in some patients?

Phase 2 data didn't show this as a clinical problem — the net effect in diabetic patients was HbA1c reduction, not worsening. But TRIUMPH-2 will give a much more granular view of individual variability. The patients where glucagon activation might cause issues (those with severe beta-cell dysfunction, very high baseline glucose, concurrent use of insulin or sulfonylureas) will be characterized.

If the diabetic arm reads out positively, the glucagon mechanism in diabetes is effectively validated at the clinical level. If there are safety signals, they'll need to be managed through label restrictions or prescriber guidance.

Timeline and What to Expect

TRIUMPH-2 and TRIUMPH-3 began enrolling in 2023–2024. Phase 3 trials of this scale typically take 18–36 months to complete enrollment and follow-up, with primary results available roughly 12–24 months after the last patient completes the trial.

If both trials read out positively, Lilly would submit a New Drug Application (NDA) to the FDA. FDA review takes approximately 6–12 months for standard review, potentially faster for priority review.

Realistically: if Phase 3 data is available in 2025–2026 and the submission is clean, FDA approval for at least one indication (obesity or diabetes) could come in 2026–2027. That's the optimistic scenario. Clinical trials can fail, have unexpected safety signals, or require additional studies.

The GLP-1 landscape is already competitive — semaglutide and tirzepatide are both entrenched. Retatrutide's path to commercial success depends on whether the Phase 3 weight-loss numbers justify a differentiated position, or whether the trial reveals tolerability challenges that narrow its viable population.

What the TRIUMPH Readouts Mean for Patients Today

For someone currently on semaglutide or tirzepatide, the TRIUMPH results matter in several ways:

• If you're not hitting your weight-loss targets on tirzepatide 15 mg, retatrutide's higher Phase 2 numbers — if they replicate in Phase 3 — represent a potential next option.
• If you have type 2 diabetes and are looking for better glycemic and weight outcomes than current options provide, TRIUMPH-2's readout will determine whether retatrutide is on the menu.
• The competitive pressure from retatrutide's development has likely accelerated Novo Nordisk and Lilly's own pipeline work — which is ultimately good for patients even if retatrutide doesn't become the dominant drug.

Until the Phase 3 data is published, everything in the public domain about retatrutide's efficacy traces back to a single Phase 2 study in a relatively small, controlled population. The TRIUMPH trials are the real test.

Related reading

• What is retatrutide? Triple agonist explained
• Tirzepatide: The Complete Guide
• SURMOUNT trial results
• GLP-1 pipeline and upcoming drugs